Medical Association for the Study of Cancer Biology and Treatment — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
belantamab mafodotin to the existing stable standard background therapyThe primary objective of the trial is to evaluate the effect of the addition of belantamab mafodotin to standard of care therapy on the titres of serum anti-dsDNA antibodies in patients with previously treated SLE. Estimand for Primary Endpoint: Change of serum anti-dsDNA antibody titers at 24 weeks of treatment vs baseline.	Lupus	Phase 2	À vérifier		À vérifier
belantamab mafodotin to the existing stable standard background therapyThe primary objective of the trial is to evaluate the effect of the addition of belantamab mafodotin to standard of care therapy on the titres of serum anti-dsDNA antibodies in patients with previously treated SLE. Estimand for Primary Endpoint: Change of serum anti-dsDNA antibody titers at 24 weeks of treatment vs baseline.	Lupus	Phase 2	À vérifier		À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
belantamab mafodotin to the existing stable standard background therapy	Lupus	Phase 2	NCT07844200	Bela-SLE — The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE.	NOT_YET_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.